Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48109


African Americans receiving a kidney transplant are considered at high risk for early rejection of their transplanted kidney and require more immunosuppression to maintain their kidney transplant function. This increase in immunosuppression puts this group at risk for drug-related toxicities and complications such as post-transplant diabetes. This study will evaluate: 1. Whether a sirolimus based steroid avoidance regimen in African Americans may decrease the risks of drug-related toxicities, 2. Decreased rates of metabolic complications such as post-transplant diabetes, 3. The effect of Sirolimus plus a reduced dose cyclosporine on renal allograft function.

Study summary:

This is an open labeled prospective trial with race matched historical controls. The treatment group (experimental arm) will be African American de novo solitary renal transplant recipients. The control arm will consist of race matched solitary renal transplant recipients who received a Cyclosporine (CsA) -based immunosuppressive regimen. The subjects will be matched for organ source (living donor vs. cadaveric). The experimental treatment arm will have an immunosuppression regimen consisting of Sirolimus, Reduced dose cyclosporine, Thymoglobulin, and only 3 doses of steroids.


Inclusion Criteria: - African American recipient race - Solitary cadaveric or living donor renal transplantation - Age ≥18years at the time of transplantation - Negative pregnancy serum test in females with childbearing potential Exclusion Criteria: - Age < 18 years at the time of transplantation - Multi-organ transplant recipient - Currently taking steroids - White Blood Cell Count < 3,000 - Platelet count < 100,000 - Triglycerides >400mg/dL - Cholesterol > 350 mg/dL - Unwillingness to comply with study procedures - Allergic reaction to sirolimus Allergy to polyclonal antilymphocyte drugs (Thymoglobulin)



Primary Contact:

Principal Investigator
Akinlolu Ojo, MD
University of Michigan

Backup Contact:


Location Contact:

Ann Arbor, Michigan 48109
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.